Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Texas Instruments, Raises Price Target to $250

Keybanc analyst John Vinh maintains Texas Instruments (NASDAQ:TXN) with a Overweight and raises the price target from $240 to $250.

byBenzinga Newsdesk

October 5, 2021

1 minute read

Keybanc analyst John Vinh maintains Texas Instruments (NASDAQ:TXN) with a Overweight and raises the price target from $240 to $250.

Silvergate Capital Late Wednesday Announced Pricing Of $200M Depositary Shares Offering

By Benzinga Newsdesk

Today, 10:26 PM

Silvergate Capital Corporation ("Silvergate" or the "Company") announced today the pricing of a public offering of 8,000,000 depositary shares, each representing 1/40th ownership interest in a share

Facebook, Google Shares See Volatility Following The Verge Report ‘Democrats unveil bill to ban online ‘surveillance advertising”

By Brent Slava

Today, 10:26 PM

https://www.theverge.com/2022/1/18/22889903/democrats-targeted-advertising-facebook-google-surveillance

HUTCHMED 2021 Oncology/Immunology Revenues $119.6M, Up 296%; Total Revenues $356M

By Bill Haddad

Today, 10:26 PM

HUTCHMED (China) (NASDAQ:HCM) will report on Q4 2021.

HCM

Hims & Hers Health Q4 EPS $(0.05) Beats $(0.07) Estimate, Sales $167.20M Beat $161.17M Estimate

By Benzinga Newsdesk

Today, 10:26 PM

Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 66.67 percent increase over losses of $(0.15) per share from

HIMS

Keybanc Maintains Overweight on Texas Instruments, Raises Price Target to $250

Related Posts

Silvergate Capital Late Wednesday Announced Pricing Of $200M Depositary Shares Offering

Facebook, Google Shares See Volatility Following The Verge Report ‘Democrats unveil bill to ban online ‘surveillance advertising”

HUTCHMED 2021 Oncology/Immunology Revenues $119.6M, Up 296%; Total Revenues $356M

Hims & Hers Health Q4 EPS $(0.05) Beats $(0.07) Estimate, Sales $167.20M Beat $161.17M Estimate